MCID: TYP010
MIFTS: 34

Type C Thymoma

Categories: Cancer diseases, Immune diseases, Endocrine diseases, Rare diseases, Genetic diseases

Aliases & Classifications for Type C Thymoma

MalaCards integrated aliases for Type C Thymoma:

Name: Type C Thymoma 12 15
Thymoma, Type C 12 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4554
NCIt 50 C7569
SNOMED-CT 68 128717008 444374006
UMLS 73 C1322286

Summaries for Type C Thymoma

MalaCards based summary : Type C Thymoma, also known as thymoma, type c, is related to thymus cancer and hormone producing pituitary cancer. An important gene associated with Type C Thymoma is SST (Somatostatin), and among its related pathways/superpathways are Salivary secretion and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Etoposide and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include thymus, thyroid and lung, and related phenotypes are nervous system and normal

Related Diseases for Type C Thymoma

Graphical network of the top 20 diseases related to Type C Thymoma:



Diseases related to Type C Thymoma

Symptoms & Phenotypes for Type C Thymoma

MGI Mouse Phenotypes related to Type C Thymoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.35 SSTR2 CD5 NGFR NTRK3 SST
2 normal MP:0002873 8.92 SST CD5 NGFR NTRK3

Drugs & Therapeutics for Type C Thymoma

Drugs for Type C Thymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
4 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
5 Liver Extracts Phase 3,Phase 1
6 Analgesics Phase 3,Phase 1
7 Central Nervous System Depressants Phase 3
8 Adjuvants, Anesthesia Phase 3
9 Narcotics Phase 3
10 Analgesics, Opioid Phase 3
11 Anesthetics Phase 3
12 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
13 Anesthetics, General Phase 3
14 Anesthetics, Intravenous Phase 3
15 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
16 Etoposide phosphate Phase 3,Phase 2,Phase 1
17 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
18 Cola Nutraceutical Phase 3,Phase 1,Not Applicable
19
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
20
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
21
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
22
Busulfan Approved, Investigational Phase 2 55-98-1 2478
23
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
24
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
25
Melphalan Approved Phase 2 148-82-3 4053 460612
26
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
27
Rabeprazole Approved, Investigational Phase 1, Phase 2 117976-89-3 5029
28
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
29
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
30
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
31
Bevacizumab Approved, Investigational Phase 2 216974-75-3
32
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
33
Belinostat Approved, Investigational Phase 2,Phase 1 866323-14-0
34
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
35
nivolumab Approved Phase 2 946414-94-4
36
Coal tar Approved Phase 1, Phase 2 8007-45-2
37
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
38
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
39
Everolimus Approved Phase 2 159351-69-6 6442177
40
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
41 Amrubicin Approved, Investigational Phase 2 110267-81-7
42
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
43
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
45
Doxil Approved June 1999 Phase 2,Phase 1 31703
46
Maleic acid Experimental Phase 2 110-16-7 444266
47
Saracatinib Investigational Phase 2 379231-04-6
48 Prednisolone acetate Phase 2
49 insulin Phase 2
50
Erlotinib Hydrochloride Phase 2 183319-69-9 176871

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
3 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
4 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
5 Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage Completed NCT00589290 Phase 2 Belinostat (PDX101)
6 Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
7 Preoperative Treatment of Patients With High Risk Thymoma Completed NCT00387868 Phase 2 cisplatin and etoposide
8 Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
9 A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
10 Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
11 Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases Completed NCT00003662 Phase 2 busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
12 Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer Completed NCT00024076 Phase 2
13 Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors Completed NCT01283945 Phase 1, Phase 2 Lucitanib
14 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
15 Study of Chemoradiotherapy for Inoperable Locally Advanced (Stage Ⅲ/Ⅳa) Thymoma or Thymic Carcinoma Recruiting NCT02636556 Phase 2
16 Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) Recruiting NCT03134118 Phase 2 Nivolumab
17 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
18 Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma Recruiting NCT02364076 Phase 2 Pembrolizumab;Epacadostat
19 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Recruiting NCT03449173 Phase 2 Sunitinib
20 Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma Recruiting NCT03466827 Phase 2 Selinexor
21 Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy Recruiting NCT03193437 Phase 2 Open Label Selinexor
22 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Recruiting NCT02810418 Phase 1, Phase 2 LMB-100;Nab-Paclitaxel
23 Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Active, not recruiting NCT02049047 Phase 2 Everolimus
24 A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Active, not recruiting NCT02623127 Phase 2 Sunitinib
25 Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma Active, not recruiting NCT01025089 Phase 2 Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
26 Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Active, not recruiting NCT01011439 Phase 2 Milciclib Maleate
27 Sunitinib for Advanced Thymus Cancer Following Earlier Treatment Active, not recruiting NCT01621568 Phase 2 Sunitinib
28 A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Active, not recruiting NCT01364727 Phase 2 Amrubicin
29 H I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors Not yet recruiting NCT03583086 Phase 1, Phase 2 VEGFR/PDGFR Dual Kinase Inhibitor X-82
30 Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer Suspended NCT03463460 Phase 2 Sunitinib Malate
31 Paclitaxel and Cisplatin for Thymic Neoplasm Terminated NCT00818090 Phase 2 paclitaxel and cisplatin
32 Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer Terminated NCT00718809 Phase 2 saracatinib
33 A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies Terminated NCT01100944 Phase 1, Phase 2 PXD101with cisplatin+doxorubicin+cyclophosphamide
34 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
35 Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma Completed NCT00314873 Phase 1 Gleevec (imatinib)
36 Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas Completed NCT01143545 Phase 1 Celecoxib;cyclophosphamide
37 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
38 Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03295227 Phase 1 Pembrolizumab
39 Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors Recruiting NCT03102320 Phase 1 Cisplatin;Gemcitabine;Anetumab ravtansine (BAY94-9343)
40 Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies Active, not recruiting NCT00921739 Phase 1
41 Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer Unknown status NCT00372840 Not Applicable
42 Biology of Thymic Tumors Completed NCT00965627
43 Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment Completed NCT03078699 Not Applicable
44 SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access Recruiting NCT02214134
45 Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Recruiting NCT01950572
46 Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer Recruiting NCT03170804
47 Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy Active, not recruiting NCT02062632 Not Applicable Doxepin Hydrochloride
48 Molecular Analysis of Thoracic Malignancies Enrolling by invitation NCT01385722
49 Preoperative Prediction of of Thymic Epithelial Tumors by Diffusion-Weighted MR Imaging Not yet recruiting NCT03212027

Search NIH Clinical Center for Type C Thymoma

Genetic Tests for Type C Thymoma

Anatomical Context for Type C Thymoma

MalaCards organs/tissues related to Type C Thymoma:

41
Thymus, Thyroid, Lung, Testes, Prostate, Liver

Publications for Type C Thymoma

Articles related to Type C Thymoma:

# Title Authors Year
1
Advanced pediatric inoperable thymus carcinoma (type C thymoma): case report on a novel therapeutic approach. ( 17984697 )
2007

Variations for Type C Thymoma

Expression for Type C Thymoma

Search GEO for disease gene expression data for Type C Thymoma.

Pathways for Type C Thymoma

Pathways related to Type C Thymoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.54 SST SSTR2
2 11.47 SST SSTR2
3 11.31 NGFR NTRK3
4 11.02 NGFR NTRK3
5
Show member pathways
10.41 NGFR NTRK3

GO Terms for Type C Thymoma

Cellular components related to Type C Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 8.92 CD5 NGFR NTRK3 SSTR2

Biological processes related to Type C Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of MAPK cascade GO:0043410 8.96 NGFR NTRK3
2 apoptotic signaling pathway GO:0097190 8.62 CD5 NGFR

Molecular functions related to Type C Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 9.16 CD5 NGFR
2 transmembrane signaling receptor activity GO:0004888 9.13 CD5 NGFR NTRK3
3 neurotrophin binding GO:0043121 8.62 NGFR NTRK3

Sources for Type C Thymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....